Insmed Inc. Files 2024 10-K Annual Report
Ticker: INSM · Form: 10-K · Filed: 2025-02-20T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
Insmed's 2024 10-K is in! Full financials for the year ending Dec 31, 2024, are out.
AI Summary
Insmed Inc. filed its 2024 10-K on February 20, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, headquartered in Bridgewater, NJ, operates in the pharmaceutical preparations sector. Key financial data and operational details for 2024, 2023, and 2022 are presented in this comprehensive annual report.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of Insmed's financial health, strategic initiatives, and risk factors for the fiscal year 2024, crucial for understanding the company's performance and future outlook.
Risk Assessment
Risk Level: medium — The filing is a standard annual report and does not inherently indicate new or elevated risks beyond typical business operations.
Key Numbers
- 2024 — Fiscal Year (Reporting period for the 10-K)
- 2023 — Fiscal Year (Prior year comparison)
- 2022 — Fiscal Year (Prior year comparison)
Key Players & Entities
- INSMED Inc (company) — Filer of the 10-K
- Bridgewater, NJ (location) — Company headquarters
- 2024-12-31 (date) — Fiscal year end
- 2025-02-20 (date) — Filing date
FAQ
What is the primary business of INSMED Inc. as indicated by its SIC code?
INSMED Inc. is classified under the SIC code 2834, which corresponds to Pharmaceutical Preparations.
On what date was the 2024 10-K filing for INSMED Inc. submitted to the SEC?
The 10-K filing for INSMED Inc. was filed on February 20, 2025.
What is the fiscal year end date for INSMED Inc.?
INSMED Inc.'s fiscal year ends on December 31st.
Where is INSMED Inc. headquartered?
INSMED Inc. is headquartered at 700 US Highway 202/206, Bridgewater, NJ 08807.
What SEC Act does this 10-K filing fall under?
This 10-K filing falls under the Securities Exchange Act of 1934.
From the Filing
0001104506-25-000009.txt : 20250220 0001104506-25-000009.hdr.sgml : 20250220 20250220070014 ACCESSION NUMBER: 0001104506-25-000009 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 128 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250220 DATE AS OF CHANGE: 20250220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 25643219 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 10-K 1 insm-20241231.htm 10-K insm-20241231 false 2024 FY 0001104506 http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member 0.0307692 0.0255384 http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure insm:reportingUnit insm:sale insm:day insm:quarterly_payment insm:payment insm:performance_condition iso4217:EUR utr:kg insm:days insm:segment 0001104506 2024-01-01 2024-12-31 0001104506 2024-06-30 0001104506 2025-02-14 0001104506 2024-10-01 2024-12-31 0001104506 2024-12-31 0001104506 2023-12-31 0001104506 2022-01-01 2022-12-31 0001104506 2023-01-01 2023-12-31 0001104506 us-gaap:CommonStockMember 2021-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001104506 us-gaap:RetainedEarningsMember 2021-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001104506 2021-12-31 0001104506 2021-01-01 2021-12-31 0001104506 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001104506 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0001104506 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0001104506 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001104506 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001104506 us-gaap:CommonStockMember 2022-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001104506 us-gaap:RetainedEarningsMember 2022-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001104506 2022-12-31 0001104506 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001104506 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001104506 us-gaap:CommonStockMember 2023-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001104506 us-gaap:RetainedEarningsMember 2023-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001104506 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001104506 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001104506 us-gaap:CommonStockMember 2024-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001104506 us-gaap:RetainedEarningsMember 2024-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001104506 insm:VertuisBioIncMember 2024